English

IMMUNOVANT, INC.

EDGAR

IMVT Quarterly report (10-Q) · filed 2026-08-06

66 filing records in this dataset, filed from 2019-04-16 to 2026-08-06. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Cash and cash equivalents: 798 million USD 2026-06-30 Source
Exact value

797800000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 206 million shares 2026-06-30 Source
Exact value

206264878 shares

Reported share-count change

20.57% · 35.2 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

171069176 shares · 2025-06-30· Source
206264878 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-538 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -126502000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -110635000 USD · 2025-10-01 – 2025-12-31 Source
Net income: -505606000 USD · 2025-04-01 – 2026-03-31 Source
Net income: -357750000 USD · 2025-04-01 – 2025-12-31 Source
Net income: -153224000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-414 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -219926000 USD · 2025-04-01 – 2025-09-30 Source
Operating cash flow: -117411000 USD · 2025-04-01 – 2025-06-30 Source
Operating cash flow: -312251000 USD · 2025-04-01 – 2025-12-31 Source
Operating cash flow: -219926000 USD · 2025-04-01 – 2025-09-30 Source
Operating cash flow: -407310000 USD · 2025-04-01 – 2026-03-31 Source
Operating cash flow: -312251000 USD · 2025-04-01 – 2025-12-31 Source
Operating cash flow: -124405000 USD · 2026-04-01 – 2026-06-30 Source

Capital expenditure

8 thousand USD

2025-04-01 – 2026-03-31

Exact inputs and evidence

Capital expenditure: 0 USD · 2025-04-01 – 2025-06-30 Source
Capital expenditure: 0 USD · 2025-04-01 – 2025-09-30 Source
Capital expenditure: 0 USD · 2025-04-01 – 2025-06-30 Source
Capital expenditure: 0 USD · 2025-04-01 – 2025-12-31 Source
Capital expenditure: 0 USD · 2025-04-01 – 2025-09-30 Source
Capital expenditure: 8000 USD · 2025-04-01 – 2026-03-31 Source
Capital expenditure: 0 USD · 2025-04-01 – 2025-12-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-06.

Financial data available through: 2026-03-31.

Coverage by financial measure

revenue: No compatible figures in this window
operating income: No compatible figures in this window
Net income: 8 of 11 periods available· newest 2026-03-31
Operating cash flow: 8 of 11 periods available· newest 2026-03-31
Capital expenditure: 8 of 11 periods available· newest 2026-03-31
Total assets: 8 of 11 periods available· newest 2026-03-31
Total liabilities: 8 of 11 periods available· newest 2026-03-31
Current assets: 8 of 11 periods available· newest 2026-03-31
Current liabilities: 8 of 11 periods available· newest 2026-03-31
Cash and cash equivalents: 8 of 11 periods available· newest 2026-03-31
long term debt: No compatible figures in this window
Shares outstanding: 8 of 11 periods available· newest 2026-03-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 91.77 million

Prior period

−USD 413.84 million

2024-04-01 – 2025-03-31
Current period

−USD 505.61 million

2025-04-01 – 2026-03-31

Exact inputs and evidence

-505606000 − -413840000 = -91766000 USD

-413840000 USD · 2024-04-01 – 2025-03-31
Inspect prior input Prior source
-505606000 USD · 2025-04-01 – 2026-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · IMMUNOVANT, INC. · 2026-03-31 IMMUNOVANT, INC. (edgar:1764013) Year-over-year change in Net income: -91766000 USD Concept: fundies:NetIncome Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -505606000 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1313235 Filing: 000176401326000064 Input fundies:NetIncome: -413840000 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1314007 Filing: 000176401326000064
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 31.44 million

Prior period

−USD 375.87 million

2024-04-01 – 2025-03-31
Current period

−USD 407.31 million

2025-04-01 – 2026-03-31

Exact inputs and evidence

-407310000 − -375874000 = -31436000 USD

-375874000 USD · 2024-04-01 – 2025-03-31
Inspect prior input Prior source
-407310000 USD · 2025-04-01 – 2026-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · IMMUNOVANT, INC. · 2026-03-31 IMMUNOVANT, INC. (edgar:1764013) Year-over-year change in Operating cash flow: -31436000 USD Concept: fundies:OperatingCashFlow Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -407310000 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1338091 Filing: 000176401326000064 Input fundies:OperatingCashFlow: -375874000 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1338743 Filing: 000176401326000064
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-98.9%

Prior period

USD 759,000

2024-04-01 – 2025-03-31
Current period

USD 8,000

2025-04-01 – 2026-03-31

Exact inputs and evidence

8000 − 759000 = -751000 USD

759000 USD · 2024-04-01 – 2025-03-31
Inspect prior input Prior source
8000 USD · 2025-04-01 – 2026-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · IMMUNOVANT, INC. · 2026-03-31 IMMUNOVANT, INC. (edgar:1764013) Year-over-year change in Capital expenditure: -751000 USD Concept: fundies:CapitalExpenditure Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 8000 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1340907 Filing: 000176401326000064 Input fundies:CapitalExpenditure: 759000 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1341463 Filing: 000176401326000064
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.

Values and sources

Revenue values and source evidence
Period	Series	Value	Source evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value	Source evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2018-04-01 – 2019-03-31	−USD 28.6 million Exact value Exact value: -28599000 USD 2018-04-01 – 2019-03-31: -28599000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMMUNOVANT, INC. · 2019-03-31 IMMUNOVANT, INC. (edgar:1764013) Net Income: -28599000 USD Concept: fundies:NetIncome Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3ANetIncome&period=2019-03-31&surface=latest&period_type=duration&start=2018-04-01&unit=USD&dimensions= Input fundies:NetIncome: -28599000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000119312520235301/imvt-20200630.xml#119190 Filing: 000119312520235301 The citation records this snapshot. The page link may show a newer release later.	−USD 28.55 million Exact value Exact value: -28547000 USD 2018-04-01 – 2019-03-31: -28547000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMMUNOVANT, INC. · 2019-03-31 IMMUNOVANT, INC. (edgar:1764013) Operating Cash Flow: -28547000 USD Concept: fundies:OperatingCashFlow Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3AOperatingCashFlow&period=2019-03-31&surface=latest&period_type=duration&start=2018-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -28547000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000119312520235301/imvt-20200630.xml#107375 Filing: 000119312520235301 The citation records this snapshot. The page link may show a newer release later.	USD 52,000 Exact value Exact value: 52000 USD 2018-04-01 – 2019-03-31: 52000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMMUNOVANT, INC. · 2019-03-31 IMMUNOVANT, INC. (edgar:1764013) Capital Expenditure: 52000 USD Concept: fundies:CapitalExpenditure Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3ACapitalExpenditure&period=2019-03-31&surface=latest&period_type=duration&start=2018-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 52000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000119312520235301/imvt-20200630.xml#114450 Filing: 000119312520235301 The citation records this snapshot. The page link may show a newer release later.	−USD 28.6 million Calculation and evidence -28547000 − 52000 USD Exact free cash flow: -28599000 USD 2018-04-01 – 2019-03-31: -28547000 USD · Inspect Operating Cash Flow · Source 2018-04-01 – 2019-03-31: 52000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMMUNOVANT, INC. · 2019-03-31 IMMUNOVANT, INC. (edgar:1764013) Free cash flow: -28599000 USD Concept: free-cash-flow Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -28547000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000119312520235301/imvt-20200630.xml#107375 Filing: 000119312520235301 Input fundies:CapitalExpenditure: 52000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000119312520235301/imvt-20200630.xml#114450 Filing: 000119312520235301 The citation records this snapshot. The page link may show a newer release later.
2020 2019-04-01 – 2020-03-31	−USD 66.39 million Exact value Exact value: -66388000 USD 2019-04-01 – 2020-03-31: -66388000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMMUNOVANT, INC. · 2020-03-31 IMMUNOVANT, INC. (edgar:1764013) Net Income: -66388000 USD Concept: fundies:NetIncome Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3ANetIncome&period=2020-03-31&surface=latest&period_type=duration&start=2019-04-01&unit=USD&dimensions= Input fundies:NetIncome: -66388000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401321000052/imvt-20210331.htm#1550515 Filing: 000176401321000052 The citation records this snapshot. The page link may show a newer release later.	−USD 53.36 million Exact value Exact value: -53357000 USD 2019-04-01 – 2020-03-31: -53357000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMMUNOVANT, INC. · 2020-03-31 IMMUNOVANT, INC. (edgar:1764013) Operating Cash Flow: -53357000 USD Concept: fundies:OperatingCashFlow Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3AOperatingCashFlow&period=2020-03-31&surface=latest&period_type=duration&start=2019-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -53357000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401321000052/imvt-20210331.htm#1583703 Filing: 000176401321000052 The citation records this snapshot. The page link may show a newer release later.	USD 31,000 Exact value Exact value: 31000 USD 2019-04-01 – 2020-03-31: 31000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMMUNOVANT, INC. · 2020-03-31 IMMUNOVANT, INC. (edgar:1764013) Capital Expenditure: 31000 USD Concept: fundies:CapitalExpenditure Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3ACapitalExpenditure&period=2020-03-31&surface=latest&period_type=duration&start=2019-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 31000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401321000052/imvt-20210331.htm#1586420 Filing: 000176401321000052 The citation records this snapshot. The page link may show a newer release later.	−USD 53.39 million Calculation and evidence -53357000 − 31000 USD Exact free cash flow: -53388000 USD 2019-04-01 – 2020-03-31: -53357000 USD · Inspect Operating Cash Flow · Source 2019-04-01 – 2020-03-31: 31000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMMUNOVANT, INC. · 2020-03-31 IMMUNOVANT, INC. (edgar:1764013) Free cash flow: -53388000 USD Concept: free-cash-flow Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -53357000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401321000052/imvt-20210331.htm#1583703 Filing: 000176401321000052 Input fundies:CapitalExpenditure: 31000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401321000052/imvt-20210331.htm#1586420 Filing: 000176401321000052 The citation records this snapshot. The page link may show a newer release later.
2021 2020-04-01 – 2021-03-31	−USD 107.43 million Exact value Exact value: -107431000 USD 2020-04-01 – 2021-03-31: -107431000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMMUNOVANT, INC. · 2021-03-31 IMMUNOVANT, INC. (edgar:1764013) Net Income: -107431000 USD Concept: fundies:NetIncome Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3ANetIncome&period=2021-03-31&surface=latest&period_type=duration&start=2020-04-01&unit=USD&dimensions= Input fundies:NetIncome: -107431000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000059/imvt-20220331.htm#1241750 Filing: 000176401322000059 The citation records this snapshot. The page link may show a newer release later.	−USD 83.33 million Exact value Exact value: -83327000 USD 2020-04-01 – 2021-03-31: -83327000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMMUNOVANT, INC. · 2021-03-31 IMMUNOVANT, INC. (edgar:1764013) Operating Cash Flow: -83327000 USD Concept: fundies:OperatingCashFlow Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3AOperatingCashFlow&period=2021-03-31&surface=latest&period_type=duration&start=2020-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -83327000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000059/imvt-20220331.htm#1268590 Filing: 000176401322000059 The citation records this snapshot. The page link may show a newer release later.	USD 210,000 Exact value Exact value: 210000 USD 2020-04-01 – 2021-03-31: 210000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMMUNOVANT, INC. · 2021-03-31 IMMUNOVANT, INC. (edgar:1764013) Capital Expenditure: 210000 USD Concept: fundies:CapitalExpenditure Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3ACapitalExpenditure&period=2021-03-31&surface=latest&period_type=duration&start=2020-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 210000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000059/imvt-20220331.htm#1271317 Filing: 000176401322000059 The citation records this snapshot. The page link may show a newer release later.	−USD 83.54 million Calculation and evidence -83327000 − 210000 USD Exact free cash flow: -83537000 USD 2020-04-01 – 2021-03-31: -83327000 USD · Inspect Operating Cash Flow · Source 2020-04-01 – 2021-03-31: 210000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMMUNOVANT, INC. · 2021-03-31 IMMUNOVANT, INC. (edgar:1764013) Free cash flow: -83537000 USD Concept: free-cash-flow Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -83327000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000059/imvt-20220331.htm#1268590 Filing: 000176401322000059 Input fundies:CapitalExpenditure: 210000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000059/imvt-20220331.htm#1271317 Filing: 000176401322000059 The citation records this snapshot. The page link may show a newer release later.
2022 2021-04-01 – 2022-03-31	−USD 156.73 million Exact value Exact value: -156730000 USD 2021-04-01 – 2022-03-31: -156730000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMMUNOVANT, INC. · 2022-03-31 IMMUNOVANT, INC. (edgar:1764013) Net Income: -156730000 USD Concept: fundies:NetIncome Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3ANetIncome&period=2022-03-31&surface=latest&period_type=duration&start=2021-04-01&unit=USD&dimensions= Input fundies:NetIncome: -156730000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000065/imvt-20230331.htm#1275400 Filing: 000176401323000065 The citation records this snapshot. The page link may show a newer release later.	−USD 106.11 million Exact value Exact value: -106112000 USD 2021-04-01 – 2022-03-31: -106112000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMMUNOVANT, INC. · 2022-03-31 IMMUNOVANT, INC. (edgar:1764013) Operating Cash Flow: -106112000 USD Concept: fundies:OperatingCashFlow Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3AOperatingCashFlow&period=2022-03-31&surface=latest&period_type=duration&start=2021-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -106112000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000065/imvt-20230331.htm#1300252 Filing: 000176401323000065 The citation records this snapshot. The page link may show a newer release later.	USD 254,000 Exact value Exact value: 254000 USD 2021-04-01 – 2022-03-31: 254000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMMUNOVANT, INC. · 2022-03-31 IMMUNOVANT, INC. (edgar:1764013) Capital Expenditure: 254000 USD Concept: fundies:CapitalExpenditure Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3ACapitalExpenditure&period=2022-03-31&surface=latest&period_type=duration&start=2021-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 254000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000065/imvt-20230331.htm#1302980 Filing: 000176401323000065 The citation records this snapshot. The page link may show a newer release later.	−USD 106.37 million Calculation and evidence -106112000 − 254000 USD Exact free cash flow: -106366000 USD 2021-04-01 – 2022-03-31: -106112000 USD · Inspect Operating Cash Flow · Source 2021-04-01 – 2022-03-31: 254000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMMUNOVANT, INC. · 2022-03-31 IMMUNOVANT, INC. (edgar:1764013) Free cash flow: -106366000 USD Concept: free-cash-flow Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -106112000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000065/imvt-20230331.htm#1300252 Filing: 000176401323000065 Input fundies:CapitalExpenditure: 254000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000065/imvt-20230331.htm#1302980 Filing: 000176401323000065 The citation records this snapshot. The page link may show a newer release later.
2023 2022-04-01 – 2023-03-31	−USD 210.96 million Exact value Exact value: -210960000 USD 2022-04-01 – 2023-03-31: -210960000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMMUNOVANT, INC. · 2023-03-31 IMMUNOVANT, INC. (edgar:1764013) Net Income: -210960000 USD Concept: fundies:NetIncome Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3ANetIncome&period=2023-03-31&surface=latest&period_type=duration&start=2022-04-01&unit=USD&dimensions= Input fundies:NetIncome: -210960000 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000092/imvt-20250331.htm#1315585 Filing: 000176401325000092 The citation records this snapshot. The page link may show a newer release later.	−USD 188.19 million Exact value Exact value: -188193000 USD 2022-04-01 – 2023-03-31: -188193000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMMUNOVANT, INC. · 2023-03-31 IMMUNOVANT, INC. (edgar:1764013) Operating Cash Flow: -188193000 USD Concept: fundies:OperatingCashFlow Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3AOperatingCashFlow&period=2023-03-31&surface=latest&period_type=duration&start=2022-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -188193000 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000092/imvt-20250331.htm#1340533 Filing: 000176401325000092 The citation records this snapshot. The page link may show a newer release later.	USD 197,000 Exact value Exact value: 197000 USD 2022-04-01 – 2023-03-31: 197000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMMUNOVANT, INC. · 2023-03-31 IMMUNOVANT, INC. (edgar:1764013) Capital Expenditure: 197000 USD Concept: fundies:CapitalExpenditure Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3ACapitalExpenditure&period=2023-03-31&surface=latest&period_type=duration&start=2022-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 197000 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000092/imvt-20250331.htm#1343186 Filing: 000176401325000092 The citation records this snapshot. The page link may show a newer release later.	−USD 188.39 million Calculation and evidence -188193000 − 197000 USD Exact free cash flow: -188390000 USD 2022-04-01 – 2023-03-31: -188193000 USD · Inspect Operating Cash Flow · Source 2022-04-01 – 2023-03-31: 197000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMMUNOVANT, INC. · 2023-03-31 IMMUNOVANT, INC. (edgar:1764013) Free cash flow: -188390000 USD Concept: free-cash-flow Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -188193000 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000092/imvt-20250331.htm#1340533 Filing: 000176401325000092 Input fundies:CapitalExpenditure: 197000 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000092/imvt-20250331.htm#1343186 Filing: 000176401325000092 The citation records this snapshot. The page link may show a newer release later.
2024 2023-04-01 – 2024-03-31	−USD 259.34 million Exact value Exact value: -259336000 USD 2023-04-01 – 2024-03-31: -259336000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMMUNOVANT, INC. · 2024-03-31 IMMUNOVANT, INC. (edgar:1764013) Net Income: -259336000 USD Concept: fundies:NetIncome Period: 2023-04-01 to 2024-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3ANetIncome&period=2024-03-31&surface=latest&period_type=duration&start=2023-04-01&unit=USD&dimensions= Input fundies:NetIncome: -259336000 USD (2023-04-01 to 2024-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1314780 Filing: 000176401326000064 The citation records this snapshot. The page link may show a newer release later.	−USD 214.23 million Exact value Exact value: -214227000 USD 2023-04-01 – 2024-03-31: -214227000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMMUNOVANT, INC. · 2024-03-31 IMMUNOVANT, INC. (edgar:1764013) Operating Cash Flow: -214227000 USD Concept: fundies:OperatingCashFlow Period: 2023-04-01 to 2024-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3AOperatingCashFlow&period=2024-03-31&surface=latest&period_type=duration&start=2023-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -214227000 USD (2023-04-01 to 2024-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1339396 Filing: 000176401326000064 The citation records this snapshot. The page link may show a newer release later.	USD 360,000 Exact value Exact value: 360000 USD 2023-04-01 – 2024-03-31: 360000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMMUNOVANT, INC. · 2024-03-31 IMMUNOVANT, INC. (edgar:1764013) Capital Expenditure: 360000 USD Concept: fundies:CapitalExpenditure Period: 2023-04-01 to 2024-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3ACapitalExpenditure&period=2024-03-31&surface=latest&period_type=duration&start=2023-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 360000 USD (2023-04-01 to 2024-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1342022 Filing: 000176401326000064 The citation records this snapshot. The page link may show a newer release later.	−USD 214.59 million Calculation and evidence -214227000 − 360000 USD Exact free cash flow: -214587000 USD 2023-04-01 – 2024-03-31: -214227000 USD · Inspect Operating Cash Flow · Source 2023-04-01 – 2024-03-31: 360000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMMUNOVANT, INC. · 2024-03-31 IMMUNOVANT, INC. (edgar:1764013) Free cash flow: -214587000 USD Concept: free-cash-flow Period: 2023-04-01 to 2024-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -214227000 USD (2023-04-01 to 2024-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1339396 Filing: 000176401326000064 Input fundies:CapitalExpenditure: 360000 USD (2023-04-01 to 2024-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1342022 Filing: 000176401326000064 The citation records this snapshot. The page link may show a newer release later.
2025 2024-04-01 – 2025-03-31	−USD 413.84 million Exact value Exact value: -413840000 USD 2024-04-01 – 2025-03-31: -413840000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMMUNOVANT, INC. · 2025-03-31 IMMUNOVANT, INC. (edgar:1764013) Net Income: -413840000 USD Concept: fundies:NetIncome Period: 2024-04-01 to 2025-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3ANetIncome&period=2025-03-31&surface=latest&period_type=duration&start=2024-04-01&unit=USD&dimensions= Input fundies:NetIncome: -413840000 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1314007 Filing: 000176401326000064 The citation records this snapshot. The page link may show a newer release later.	−USD 375.87 million Exact value Exact value: -375874000 USD 2024-04-01 – 2025-03-31: -375874000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMMUNOVANT, INC. · 2025-03-31 IMMUNOVANT, INC. (edgar:1764013) Operating Cash Flow: -375874000 USD Concept: fundies:OperatingCashFlow Period: 2024-04-01 to 2025-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3AOperatingCashFlow&period=2025-03-31&surface=latest&period_type=duration&start=2024-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -375874000 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1338743 Filing: 000176401326000064 The citation records this snapshot. The page link may show a newer release later.	USD 759,000 Exact value Exact value: 759000 USD 2024-04-01 – 2025-03-31: 759000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMMUNOVANT, INC. · 2025-03-31 IMMUNOVANT, INC. (edgar:1764013) Capital Expenditure: 759000 USD Concept: fundies:CapitalExpenditure Period: 2024-04-01 to 2025-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3ACapitalExpenditure&period=2025-03-31&surface=latest&period_type=duration&start=2024-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 759000 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1341463 Filing: 000176401326000064 The citation records this snapshot. The page link may show a newer release later.	−USD 376.63 million Calculation and evidence -375874000 − 759000 USD Exact free cash flow: -376633000 USD 2024-04-01 – 2025-03-31: -375874000 USD · Inspect Operating Cash Flow · Source 2024-04-01 – 2025-03-31: 759000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMMUNOVANT, INC. · 2025-03-31 IMMUNOVANT, INC. (edgar:1764013) Free cash flow: -376633000 USD Concept: free-cash-flow Period: 2024-04-01 to 2025-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -375874000 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1338743 Filing: 000176401326000064 Input fundies:CapitalExpenditure: 759000 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1341463 Filing: 000176401326000064 The citation records this snapshot. The page link may show a newer release later.
2026 2025-04-01 – 2026-03-31	−USD 505.61 million Exact value Exact value: -505606000 USD 2025-04-01 – 2026-03-31: -505606000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMMUNOVANT, INC. · 2026-03-31 IMMUNOVANT, INC. (edgar:1764013) Net Income: -505606000 USD Concept: fundies:NetIncome Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3ANetIncome&period=2026-03-31&surface=latest&period_type=duration&start=2025-04-01&unit=USD&dimensions= Input fundies:NetIncome: -505606000 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1313235 Filing: 000176401326000064 The citation records this snapshot. The page link may show a newer release later.	−USD 407.31 million Exact value Exact value: -407310000 USD 2025-04-01 – 2026-03-31: -407310000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMMUNOVANT, INC. · 2026-03-31 IMMUNOVANT, INC. (edgar:1764013) Operating Cash Flow: -407310000 USD Concept: fundies:OperatingCashFlow Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3AOperatingCashFlow&period=2026-03-31&surface=latest&period_type=duration&start=2025-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -407310000 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1338091 Filing: 000176401326000064 The citation records this snapshot. The page link may show a newer release later.	USD 8,000 Exact value Exact value: 8000 USD 2025-04-01 – 2026-03-31: 8000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMMUNOVANT, INC. · 2026-03-31 IMMUNOVANT, INC. (edgar:1764013) Capital Expenditure: 8000 USD Concept: fundies:CapitalExpenditure Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013/explain?concept=fundies%3ACapitalExpenditure&period=2026-03-31&surface=latest&period_type=duration&start=2025-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8000 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1340907 Filing: 000176401326000064 The citation records this snapshot. The page link may show a newer release later.	−USD 407.32 million Calculation and evidence -407310000 − 8000 USD Exact free cash flow: -407318000 USD 2025-04-01 – 2026-03-31: -407310000 USD · Inspect Operating Cash Flow · Source 2025-04-01 – 2026-03-31: 8000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMMUNOVANT, INC. · 2026-03-31 IMMUNOVANT, INC. (edgar:1764013) Free cash flow: -407318000 USD Concept: free-cash-flow Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T16:50:31Z Snapshot: 369614a8857b44aae5a2d3b634b38a563f19083b864133df3446f67194527fcc Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764013?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -407310000 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1338091 Filing: 000176401326000064 Input fundies:CapitalExpenditure: 8000 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm#1340907 Filing: 000176401326000064 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

66 filings · 1,759 latest values · 1,759 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001764013, 1764013, IMVT, edgar:1764013

Also known as Health Sciences Acquisitions Corp, IMMUNOVANT, INC., Immunovant, Inc.

IMMUNOVANT, INC.

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

Growth

Profit and cash

Balance sheet

Cash generation